• Ruxolitinib Phosphate Triggers Apoptosis and Pyroptosis in A

  2026-06-11

  A recent study reveals that Ruxolitinib phosphate (INCB018424) induces both apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma (ATC) by inhibiting DRP1-mediated mitochondrial fission through suppression of the JAK1/2-STAT3 pathway. This mechanistic insight highlights new avenues for targeted therapies in highly aggressive thyroid cancers.

• Polyethylenimine Linear (PEI MW 40,000): Nanoparticle Engine

  2026-06-11

  Explore how Polyethylenimine Linear (PEI MW 40,000) enables precision DNA transfection and advances in nanoparticle engineering for in vitro studies. This article reveals new scientific insights and practical considerations for maximizing transfection efficiency across variable assay formats.

• Cefodizime: Third-Generation Cephalosporin for Advanced Assa

  2026-06-10

  Cefodizime stands apart as a third-generation cephalosporin antibiotic with robust immunomodulatory and kidney-sparing properties, making it a prime choice for modeling complex infections and resistance in research settings. This article translates recent clinical and bench findings into actionable workflows, troubleshooting strategies, and protocol enhancements for infectious disease research.

• Cyanine 3 Tyramide: Fluorescent Dye for Biomedical Research

  2026-06-10

  Cyanine 3 Tyramide is a high-sensitivity fluorescent dye for biomedical research, enabling robust signal amplification in immunohistochemistry and in situ hybridization. Its use in Tyramide Signal Amplification workflows allows detection of low-abundance targets in complex tissue. This article details the mechanism, evidence, and best practices for employing Cyanine 3 Tyramide in molecular biology studies.

• Temafloxacin: Pharmacokinetics and Antibacterial Spectrum

  2026-06-09

  Temafloxacin is a fluoroquinolone broad-spectrum antibacterial agent with high oral bioavailability, potent activity against Gram-positive and Gram-negative pathogens, and validated use in both in vitro and in vivo models. Its pharmacokinetic properties enable flexible dosing, making it valuable for infection biology research and antibacterial agent benchmarking.

• Ionomycin Free Acid: Advancing Calcium Signaling Insights in

  2026-06-09

  This thought-leadership article explores how Ionomycin free acid empowers translational researchers to decode calcium signaling in aggressive cancers such as triple negative breast cancer (TNBC). By integrating mechanistic evidence from recent studies on lncRNA FAISL-mediated regulation of FAK stability, the article guides strategic experimental design and highlights the translational implications of precise calcium ionophore use.

• Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial A

  2026-06-08

  Temafloxacin stands out as a fluoroquinolone broad-spectrum antibacterial agent with proven potency against both Gram-positive and Gram-negative bacteria, including challenging intracellular pathogens. This article translates core experimental strategies and troubleshooting insights into actionable guidance, empowering researchers to optimize respiratory and intracellular infection models using Temafloxacin from APExBIO.

• Lipo3K Transfection Reagent: High-Efficiency Delivery in Dif

  2026-06-08

  Lipo3K Transfection Reagent empowers researchers to achieve exceptional nucleic acid delivery in even the most challenging cell models, thanks to its dual-component lipid formulation and low cytotoxicity. From advanced kidney organoid assays to streamlined DNA and siRNA co-transfection workflows, this APExBIO reagent unlocks new frontiers in gene expression and RNA interference research.

• Cefodizime (SKU BA1050): Reproducible Solutions for Cell-Bas

  2026-06-07

  This article addresses real laboratory challenges in cell viability and cytotoxicity assays, focusing on how Cefodizime (SKU BA1050) provides data-backed, reproducible solutions. Drawing on peer-reviewed studies and product documentation, it guides researchers in protocol optimization, data interpretation, and reliable vendor selection for advanced research applications.

• Amikacin (BAY416651) Workflows in Antibiotic Resistance Rese

  2026-06-06

  Amikacin (BAY416651) stands out for its robustness against most aminoglycoside-modifying enzymes, making it a gold standard for modeling multidrug resistance and transmission dynamics. This guide delivers workflow optimizations, troubleshooting insights, and practical assay choices for leveraging Amikacin in advanced resistance research.

• Ceftolozane Sulfate: Strategic Leverage for Translational An

  2026-06-05

  This article explores the mechanistic, experimental, and translational positioning of Ceftolozane sulfate as a keystone agent against multidrug-resistant Gram-negative pathogens, with a focus on Pseudomonas aeruginosa. We unite recent in vitro, PK/PD, and resistance studies to provide actionable guidance for researchers designing robust antibacterial workflows and navigating the evolving clinical landscape.

• Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial A

  2026-06-05

  Temafloxacin empowers research on Gram-positive and Gram-negative pathogens with robust, reproducible antibacterial activity and exceptional tissue penetration. This guide delivers workflow enhancements, troubleshooting strategies, and data-backed protocol parameters for both respiratory and intracellular infection models.

• Synergistic Inhibition of EMT in Pancreatic Cancer via CDK4/

  2026-06-04

  Gu et al. (2025) reveal that combining CDK4/6 and BET inhibitors yields a synergistic suppression of pancreatic ductal adenocarcinoma growth and epithelial-mesenchymal transition (EMT) by co-regulating the GSK3β-mediated Wnt/β-catenin and TGF-β/Smad pathways. This dual-targeted approach suggests a promising therapeutic strategy for overcoming the limitations of single-agent treatments in aggressive pancreatic cancer.

• Cefazedone (Refosporen): Optimized Workflows & Troubleshooti

  2026-06-04

  Cefazedone (Refosporen) delivers robust, β-lactamase-resistant efficacy in both in vitro and translational models of Gram-positive and Gram-negative infections. This guide translates cutting-edge reference data and real-world troubleshooting into actionable steps, helping researchers maximize antibacterial testing reliability and PK/PD-driven outcomes.

• Cefodizime: Third-Generation Cephalosporin in AMR Research

  2026-06-03

  Cefodizime, a third-generation cephalosporin antibiotic, empowers researchers to dissect antimicrobial resistance and model clinically relevant infections. Its robust spectrum, β-lactamase stability, and unique immunomodulatory properties make it a standout tool for high-fidelity microbiology workflows.

452 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page